Genentech Announces $750 Million Injectable Medicine Manufacturing Expansion in Hillsboro, Oregon

Genentech, a member of the Roche Group, announced on August 20 plans to invest approximately $750 million in a new device fill-finish manufacturing facility at its 75-acre campus in Hillsboro, Oregon.

Doubling the Hillsboro facility

The investment will double the size of the existing facility and is expected to create an additional 250 specialized manufacturing jobs, with commercial operations expected to begin in 2031.

Pre-filled syringes and autoinjectors

The new facility will support the manufacturing of advanced drug delivery devices, including pre-filled syringes and autoinjectors. It is designed to offer flexible manufacturing capacity across both high- and low-volume device filling to respond to the evolving needs of Roche and Genentech’s pipeline.

Following Holly Springs

The Hillsboro investment follows the recent topping out of Genentech’s new manufacturing facility in Holly Springs, North Carolina, which is designed to support metabolic medicines, including next-generation obesity treatments.